NEW YORK, Sept. 24 (GenomeWeb News) - SomaLogic has signed on to an IP alliance with Archemix, a biopharma based in Cambridge, Mass., for use of aptamers in diagnosis and therapeutics, the companies said Tuesday.
Under the agreement, SomaLogic, of Boulder, Colo., will have exclusive rights to diagnostics and ex vivo detection applications of aptamer technology, while Archemix has rights to therapeutics based on aptamers. For drug screening and target validation, the companies will cross-license the technologies.
The companies have also agreed to jointly "maintain , expand, and defend the aptamer patent estate," which includes over 150 patents and 100 patent applications, according to a press statement.
Aptamers are single-stranded nucleic acids will three-dimensional shapes that enable them to bind specifically to target molecules with high affinity.